ALS 8176

Drug Profile

ALS 8176

Alternative Names: AL 8176; ALS 008176; ALS8176; JNJ-64041575

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Nucleosides
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 17 Jan 2017 Preclinical trials in Metapneumovirus-infections in USA (PO) (Alios BioPharma pipeline, January 2017)
  • 17 Jan 2017 Preclinical trials in Parainfluenza virus infections in USA (PO) (Alios BioPharma pipeline, January 2017)
  • 05 Jan 2017 Alios Biopharma suspends phase-I clinical trial in Respiratory syncytial virus infections (In infants) in United Kingdom, Thailand, Taiwan, South Africa, Romania, Panama, New Zealand, Japan, France, Colombia, Chile, Canada, Australia, USA (PO) (NCT02202356)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top